Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDC Documents Library

This article was originally published in The Gray Sheet

Executive Summary

Recent additions to the library include an FDA FDL-1warning letter to BioImagene about its PATHIAM image analysis software, the CDRH Office of Science FDL-2Annual Report for 2004, and the HHS FDL-3Inspector General Office letter to Senate Health Committee Chairman Mike Enzi (R-Wyo.) regarding four personal conduct allegations about FDA Commissioner-Nominee Lester Crawford. Sign up for a free twice-monthly email alert of new documents at 1http://www.fdceports.com/documentsalert and browse the Library at 2http://www.fdcreports.com/documents...

You may also be interested in...



Former MiMedX Execs Convicted On Securities Fraud Charges

The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.

First-Of-Its-Kind Prostate Cancer Imaging Agent Approved By FDA

Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.

GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel